[8-K] Maravai LifeSciences Holdings, Inc. Reports Material Event
Maravai LifeSciences announced a corporate restructuring to reduce operating costs, including a workforce reduction that management committed to on August 8, 2025. The company expects the reduction to affect approximately 25% of its workforce and estimates restructuring and related costs of $8.0 million to $9.0 million, primarily for severance and benefits, with the majority expected to be recognized in the second half of 2025. The company cautions the estimate is based on current assumptions and actual amounts may differ or include additional costs.
The Board eliminated two executive roles on August 7, 2025, resulting in the planned departures of Rebecca Buzzeo, Executive VP and Chief Commercial Officer, and Pete Leddy, Ph.D., Executive VP and Chief Administrative Officer, with expected last days of employment in September and October 2025. Their termination is treated as without "cause" under their agreements, and severance amounts are included in the estimated restructuring costs, subject to execution of separation agreements and releases. The press release with second-quarter results is furnished as Exhibit 99.1.
Maravai LifeSciences ha annunciato una riorganizzazione aziendale volta a ridurre i costi operativi, comprensiva di una riduzione dell'organico che la direzione ha deciso l'8 agosto 2025. L'azienda prevede che la misura interesser脿 circa il 25% del personale e stima costi di ristrutturazione e correlati per $8,0 milioni - $9,0 milioni, principalmente per indennit脿 di licenziamento e benefit, con la maggior parte che dovrebbe essere rilevata nella seconda met脿 del 2025. La societ脿 avverte che la stima si basa su ipotesi correnti e gli importi effettivi potrebbero variare o includere costi aggiuntivi.
Il Consiglio ha eliminato due ruoli dirigenziali il 7 agosto 2025, determinando le uscite pianificate di Rebecca Buzzeo, Executive VP e Chief Commercial Officer, e di Pete Leddy, Ph.D., Executive VP e Chief Administrative Officer, con ultime giornate di impiego previste a settembre e ottobre 2025. La loro cessazione 猫 trattata come senza "causa" ai sensi dei relativi accordi, e gli importi delle indennit脿 di licenziamento sono inclusi nella stima dei costi di ristrutturazione, subordinati alla sottoscrizione di accordi di separazione e relative liberatorie. Il comunicato stampa con i risultati del secondo trimestre 猫 fornito come Allegato 99.1.
Maravai LifeSciences anunci贸 una reestructuraci贸n corporativa para reducir los costos operativos, que incluye una reducci贸n de personal que la direcci贸n aprob贸 el 8 de agosto de 2025. La compa帽铆a espera que la reducci贸n afecte a aproximadamente el 25% de su plantilla y estima costos de reestructuraci贸n y relacionados de $8.0 a $9.0 millones, principalmente por indemnizaciones y beneficios, y prev茅 que la mayor parte se reconozca en la segunda mitad de 2025. La empresa advierte que la estimaci贸n se basa en supuestos actuales y que los importes reales podr铆an variar o incluir costes adicionales.
La Junta elimin贸 dos cargos ejecutivos el 7 de agosto de 2025, lo que provoc贸 las salidas planificadas de Rebecca Buzzeo, Vicepresidenta Ejecutiva y Directora Comercial, y de Pete Leddy, Ph.D., Vicepresidente Ejecutivo y Director Administrativo, con 煤ltimos d铆as esperados de empleo en septiembre y octubre de 2025. Sus terminaciones se tratan como sin "causa" seg煤n sus acuerdos, y las cuant铆as de las indemnizaciones est谩n incluidas en la estimaci贸n de costos de reestructuraci贸n, sujetas a la firma de acuerdos de separaci贸n y cesiones. El comunicado de prensa con los resultados del segundo trimestre se presenta como Anexo 99.1.
Maravai LifeSciences電� 鞖挫榿牍勳毄鞚� 鞝堦皭頃橁赴 鞙勴暅 旮办梾 甑“臁办爼鞚� 氚滍憸頄堨溂氅�, 鞐赴鞐愲姅 瓴届榿歆勳澊 2025雲� 8鞗� 8鞚� 瓴办爼頃� 鞚鸽牓 臧愳稌鞚� 韽暔霅╇媹雼�. 須岇偓電� 臧愳稌鞚� 鞝勳泊 鞚鸽牓鞚� 鞎� 25%鞐� 鞓來枼鞚� 氙胳範 瓴冹溂搿� 鞓堨儊頃橂┌, 韲挫旮� 氚� 氤惦Μ頉勳儩鞚� 欤茧 頃� $8.0M~$9.0M 攴滊鞚� 甑“臁办爼 氚� 甏�霠� 牍勳毄鞚� 於旍爼頃橁碃 鞛堨溂氅�, 攴� 雽�攵�攵勳潃 2025雲� 頃橂皹旮�鞐� 鞚胳嫕霅� 瓴冹溂搿� 氤搓碃 鞛堨姷雼堧嫟. 須岇偓電� 鞚� 於旍爼旃橁皜 順勳灛鞚� 臧�鞝曥棎 旮半皹頃� 瓴冹澊氅� 鞁れ牅 旮堨暋鞚� 雼澕歆�瓯半倶 於旉皜 牍勳毄鞚� 韽暔霅� 靾� 鞛堧嫟瓿� 瓴疥碃頃╇媹雼�.
鞚挫偓須岆姅 2025雲� 8鞗� 7鞚� 霊� 臧滌潣 鞛勳洂歆侅潉 韽愳頃橃棳 Rebecca Buzzeo, Executive VP 氚� Chief Commercial Officer鞕赌 Pete Leddy, Ph.D., Executive VP 氚� Chief Administrative Officer鞚� 瓿勴殟霅� 韲挫瀯鞚� 齑堧灅頄堨溂氅�, 毵堨毵� 攴茧鞚检潃 2025雲� 9鞗� 氚� 10鞗旊 鞓堨儊霅╇媹雼�. 鞚措摛鞚� 頃挫瀯鞚� 頃措嫻 瓿勳暯鞐� 霐半澕 "靷湢 鞐嗢潓(without \"cause\")"鞙茧 觳橂Μ霅橂┌, 韲挫旮� 鞎§垬電� 甑“臁办爼 牍勳毄 於旍爼旃橃棎 韽暔霅橃柎 鞛堨溂雮� 攵勲Μ 頃╈潣靹� 氚� 氅挫眳靹� 觳搓舶鞚� 臁瓣贝鞛呺媹雼�. 2攵勱赴 鞁れ爜鞚� 雼挫潃 氤措弰鞛愲電� Exhibit 99.1搿� 鞝滌稖霅橃柎 鞛堨姷雼堧嫟.
Maravai LifeSciences a annonc茅 une restructuration d'entreprise visant 脿 r茅duire les co没ts d'exploitation, incluant une r茅duction des effectifs que la direction a d茅cid茅e le 8 ao没t 2025. La soci茅t茅 pr茅voit que cette r茅duction concernera environ 25% de ses salari茅s et estime les co没ts de restructuration et li茅s entre 8,0 et 9,0 millions de dollars, principalement pour des indemnit茅s de d茅part et des avantages, la majeure partie devant 锚tre comptabilis茅e au second semestre 2025. La soci茅t茅 pr茅cise que cette estimation repose sur des hypoth猫ses actuelles et que les montants r茅els pourraient diff茅rer ou inclure des co没ts suppl茅mentaires.
Le conseil d'administration a supprim茅 deux postes de direction le 7 ao没t 2025, entra卯nant les d茅parts pr茅vus de Rebecca Buzzeo, Vice-pr茅sidente ex茅cutive et Directrice commerciale, et de Pete Leddy, Ph.D., Vice-pr茅sident ex茅cutif et Directeur administratif, leurs derniers jours de travail 茅tant attendus en septembre et octobre 2025. Leur cessation est trait茅e comme sans "cause" conform茅ment 脿 leurs accords, et les montants d'indemnit茅s sont inclus dans l'estimation des co没ts de restructuration, sous r茅serve de la signature d'accords de s茅paration et de d茅charges. Le communiqu茅 de presse contenant les r茅sultats du deuxi猫me trimestre est fourni en tant qu'Annexe 99.1.
Maravai LifeSciences k眉ndigte eine Unternehmensumstrukturierung zur Senkung der Betriebskosten an, einschlie脽lich eines Stellenabbaus, dem das Management am 8. August 2025 zugestimmt hat. Das Unternehmen erwartet, dass die Reduzierung etwa 25% der Belegschaft betrifft, und sch盲tzt Restrukturierungs- und damit verbundene Kosten in H枚he von $8,0 Millionen bis $9,0 Millionen, haupts盲chlich f眉r Abfindungen und Sozialleistungen; der Gro脽teil soll in der zweiten H盲lfte des Jahres 2025 erfasst werden. Das Unternehmen weist darauf hin, dass die Sch盲tzung auf den derzeitigen Annahmen beruht und die tats盲chlichen Betr盲ge abweichen oder zus盲tzliche Kosten enthalten k枚nnen.
Der Vorstand strich am 7. August 2025 zwei F眉hrungspositionen, was zu den geplanten Abg盲ngen von Rebecca Buzzeo, Executive VP und Chief Commercial Officer, und Pete Leddy, Ph.D., Executive VP und Chief Administrative Officer f眉hrte; deren voraussichtliche letzte Arbeitstage sind im September bzw. Oktober 2025. Ihre Beendigung wird gem盲脽 ihren Vereinbarungen als ohne "cause" behandelt, und die Abfindungsbetr盲ge sind in den gesch盲tzten Restrukturierungskosten enthalten, vorbehaltlich der Unterzeichnung von Trennungsvereinbarungen und Freigaben. Die Pressemitteilung mit den Ergebnissen des zweiten Quartals ist als Exhibit 99.1 beigef眉gt.
- Company disclosed a clear cost-reduction initiative and is taking concrete action to reduce operating costs.
- Estimated restructuring range provided ($8.0M鈥�$9.0M), giving investors a quantified view of near-term charges.
- Majority of costs expected to be recognized in H2 2025, offering timing transparency for financial modeling.
- Approximately 25% of the workforce is expected to be affected, representing a significant operational change.
- Near-term restructuring costs of $8.0M鈥�$9.0M will pressure earnings and cash flow in 2025.
- Elimination of two senior executive roles (Chief Commercial Officer and Chief Administrative Officer) may disrupt operations during transition.
- Estimate is subject to change and Company may incur additional unanticipated costs related to the workforce reduction.
Insights
TL;DR Restructuring reduces ongoing cost base but triggers near-term charges of $8.0M鈥�$9.0M and removes senior commercial and administrative leadership.
The announced workforce reduction affecting ~25% of employees and the $8.0M鈥�$9.0M estimated charge are material near-term impacts to operating expenses and cash flow timing for 2025. The majority of charges are expected in H2 2025, which will depress reported results in that period but could lower future operating expenses if headcount reductions achieve intended savings. The company鈥檚 qualification that actual costs may differ highlights execution risk and potential for additional cash outlays beyond the disclosed range.
TL;DR Board-level eliminations of two EVP roles signal substantive organizational change and raise succession and oversight questions.
Eliminating the Chief Commercial Officer and Chief Administrative Officer positions is a significant governance action that concentrates responsibility and may affect commercial execution and administration during transition. The filing notes severance obligations under existing employment agreements and conditions tied to separation agreements and releases, which is standard but increases near-term liabilities. Stakeholders should note the formal disclosure and clarity on inclusion of these costs in the restructuring estimate, although additional contingent costs remain possible.
Maravai LifeSciences ha annunciato una riorganizzazione aziendale volta a ridurre i costi operativi, comprensiva di una riduzione dell'organico che la direzione ha deciso l'8 agosto 2025. L'azienda prevede che la misura interesser脿 circa il 25% del personale e stima costi di ristrutturazione e correlati per $8,0 milioni - $9,0 milioni, principalmente per indennit脿 di licenziamento e benefit, con la maggior parte che dovrebbe essere rilevata nella seconda met脿 del 2025. La societ脿 avverte che la stima si basa su ipotesi correnti e gli importi effettivi potrebbero variare o includere costi aggiuntivi.
Il Consiglio ha eliminato due ruoli dirigenziali il 7 agosto 2025, determinando le uscite pianificate di Rebecca Buzzeo, Executive VP e Chief Commercial Officer, e di Pete Leddy, Ph.D., Executive VP e Chief Administrative Officer, con ultime giornate di impiego previste a settembre e ottobre 2025. La loro cessazione 猫 trattata come senza "causa" ai sensi dei relativi accordi, e gli importi delle indennit脿 di licenziamento sono inclusi nella stima dei costi di ristrutturazione, subordinati alla sottoscrizione di accordi di separazione e relative liberatorie. Il comunicato stampa con i risultati del secondo trimestre 猫 fornito come Allegato 99.1.
Maravai LifeSciences anunci贸 una reestructuraci贸n corporativa para reducir los costos operativos, que incluye una reducci贸n de personal que la direcci贸n aprob贸 el 8 de agosto de 2025. La compa帽铆a espera que la reducci贸n afecte a aproximadamente el 25% de su plantilla y estima costos de reestructuraci贸n y relacionados de $8.0 a $9.0 millones, principalmente por indemnizaciones y beneficios, y prev茅 que la mayor parte se reconozca en la segunda mitad de 2025. La empresa advierte que la estimaci贸n se basa en supuestos actuales y que los importes reales podr铆an variar o incluir costes adicionales.
La Junta elimin贸 dos cargos ejecutivos el 7 de agosto de 2025, lo que provoc贸 las salidas planificadas de Rebecca Buzzeo, Vicepresidenta Ejecutiva y Directora Comercial, y de Pete Leddy, Ph.D., Vicepresidente Ejecutivo y Director Administrativo, con 煤ltimos d铆as esperados de empleo en septiembre y octubre de 2025. Sus terminaciones se tratan como sin "causa" seg煤n sus acuerdos, y las cuant铆as de las indemnizaciones est谩n incluidas en la estimaci贸n de costos de reestructuraci贸n, sujetas a la firma de acuerdos de separaci贸n y cesiones. El comunicado de prensa con los resultados del segundo trimestre se presenta como Anexo 99.1.
Maravai LifeSciences電� 鞖挫榿牍勳毄鞚� 鞝堦皭頃橁赴 鞙勴暅 旮办梾 甑“臁办爼鞚� 氚滍憸頄堨溂氅�, 鞐赴鞐愲姅 瓴届榿歆勳澊 2025雲� 8鞗� 8鞚� 瓴办爼頃� 鞚鸽牓 臧愳稌鞚� 韽暔霅╇媹雼�. 須岇偓電� 臧愳稌鞚� 鞝勳泊 鞚鸽牓鞚� 鞎� 25%鞐� 鞓來枼鞚� 氙胳範 瓴冹溂搿� 鞓堨儊頃橂┌, 韲挫旮� 氚� 氤惦Μ頉勳儩鞚� 欤茧 頃� $8.0M~$9.0M 攴滊鞚� 甑“臁办爼 氚� 甏�霠� 牍勳毄鞚� 於旍爼頃橁碃 鞛堨溂氅�, 攴� 雽�攵�攵勳潃 2025雲� 頃橂皹旮�鞐� 鞚胳嫕霅� 瓴冹溂搿� 氤搓碃 鞛堨姷雼堧嫟. 須岇偓電� 鞚� 於旍爼旃橁皜 順勳灛鞚� 臧�鞝曥棎 旮半皹頃� 瓴冹澊氅� 鞁れ牅 旮堨暋鞚� 雼澕歆�瓯半倶 於旉皜 牍勳毄鞚� 韽暔霅� 靾� 鞛堧嫟瓿� 瓴疥碃頃╇媹雼�.
鞚挫偓須岆姅 2025雲� 8鞗� 7鞚� 霊� 臧滌潣 鞛勳洂歆侅潉 韽愳頃橃棳 Rebecca Buzzeo, Executive VP 氚� Chief Commercial Officer鞕赌 Pete Leddy, Ph.D., Executive VP 氚� Chief Administrative Officer鞚� 瓿勴殟霅� 韲挫瀯鞚� 齑堧灅頄堨溂氅�, 毵堨毵� 攴茧鞚检潃 2025雲� 9鞗� 氚� 10鞗旊 鞓堨儊霅╇媹雼�. 鞚措摛鞚� 頃挫瀯鞚� 頃措嫻 瓿勳暯鞐� 霐半澕 "靷湢 鞐嗢潓(without \"cause\")"鞙茧 觳橂Μ霅橂┌, 韲挫旮� 鞎§垬電� 甑“臁办爼 牍勳毄 於旍爼旃橃棎 韽暔霅橃柎 鞛堨溂雮� 攵勲Μ 頃╈潣靹� 氚� 氅挫眳靹� 觳搓舶鞚� 臁瓣贝鞛呺媹雼�. 2攵勱赴 鞁れ爜鞚� 雼挫潃 氤措弰鞛愲電� Exhibit 99.1搿� 鞝滌稖霅橃柎 鞛堨姷雼堧嫟.
Maravai LifeSciences a annonc茅 une restructuration d'entreprise visant 脿 r茅duire les co没ts d'exploitation, incluant une r茅duction des effectifs que la direction a d茅cid茅e le 8 ao没t 2025. La soci茅t茅 pr茅voit que cette r茅duction concernera environ 25% de ses salari茅s et estime les co没ts de restructuration et li茅s entre 8,0 et 9,0 millions de dollars, principalement pour des indemnit茅s de d茅part et des avantages, la majeure partie devant 锚tre comptabilis茅e au second semestre 2025. La soci茅t茅 pr茅cise que cette estimation repose sur des hypoth猫ses actuelles et que les montants r茅els pourraient diff茅rer ou inclure des co没ts suppl茅mentaires.
Le conseil d'administration a supprim茅 deux postes de direction le 7 ao没t 2025, entra卯nant les d茅parts pr茅vus de Rebecca Buzzeo, Vice-pr茅sidente ex茅cutive et Directrice commerciale, et de Pete Leddy, Ph.D., Vice-pr茅sident ex茅cutif et Directeur administratif, leurs derniers jours de travail 茅tant attendus en septembre et octobre 2025. Leur cessation est trait茅e comme sans "cause" conform茅ment 脿 leurs accords, et les montants d'indemnit茅s sont inclus dans l'estimation des co没ts de restructuration, sous r茅serve de la signature d'accords de s茅paration et de d茅charges. Le communiqu茅 de presse contenant les r茅sultats du deuxi猫me trimestre est fourni en tant qu'Annexe 99.1.
Maravai LifeSciences k眉ndigte eine Unternehmensumstrukturierung zur Senkung der Betriebskosten an, einschlie脽lich eines Stellenabbaus, dem das Management am 8. August 2025 zugestimmt hat. Das Unternehmen erwartet, dass die Reduzierung etwa 25% der Belegschaft betrifft, und sch盲tzt Restrukturierungs- und damit verbundene Kosten in H枚he von $8,0 Millionen bis $9,0 Millionen, haupts盲chlich f眉r Abfindungen und Sozialleistungen; der Gro脽teil soll in der zweiten H盲lfte des Jahres 2025 erfasst werden. Das Unternehmen weist darauf hin, dass die Sch盲tzung auf den derzeitigen Annahmen beruht und die tats盲chlichen Betr盲ge abweichen oder zus盲tzliche Kosten enthalten k枚nnen.
Der Vorstand strich am 7. August 2025 zwei F眉hrungspositionen, was zu den geplanten Abg盲ngen von Rebecca Buzzeo, Executive VP und Chief Commercial Officer, und Pete Leddy, Ph.D., Executive VP und Chief Administrative Officer f眉hrte; deren voraussichtliche letzte Arbeitstage sind im September bzw. Oktober 2025. Ihre Beendigung wird gem盲脽 ihren Vereinbarungen als ohne "cause" behandelt, und die Abfindungsbetr盲ge sind in den gesch盲tzten Restrukturierungskosten enthalten, vorbehaltlich der Unterzeichnung von Trennungsvereinbarungen und Freigaben. Die Pressemitteilung mit den Ergebnissen des zweiten Quartals ist als Exhibit 99.1 beigef眉gt.
FAQ
What did Maravai (MRVI) announce regarding workforce reductions?
How much does Maravai (MRVI) expect to incur in restructuring costs?
When will Maravai recognize the restructuring costs?
Which executives are leaving Maravai (MRVI) as a result of the restructuring?
Will departing executives receive severance from Maravai (MRVI)?
Where can I find the press release with Maravai's second-quarter 2025 results?
